Factors Supporting Teva Pharmaceutical’s (TEVA) Long-Term Profitability

2 hours ago 3

Soumya Eswaran

Tue, April 7, 2026 astatine 8:19 AM CDT 3 min read

TCW funds, an concern absorption company, released its “TCW Relative Value Mid Cap Fund” fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. Equities finished the twelvemonth connected a affirmative note, with the S&P 500 Total Return (USD) expanding by 2.65% and achieving a singular 17.9% successful 2025. The AI assemblage continued to thrive pursuing Trump's tariff announcements. While determination are concerning indicators that echo the Dot-Com bubble, the underlying companies look to beryllium defying likelihood with technological advancements, beardown financials, and tenable valuations. Looking ahead, the steadfast anticipates the equity marketplace volition stay highly delicate to argumentation changes and net reports, with valuations staying adjacent historically precocious levels. Class I shares of the money returned 4.54% successful Q4, outperforming the Russell Midcap® Value Index benchmark, which returned 1.42%. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its fourth-quarter 2025 capitalist letter, TCW Relative Value Mid Cap Fund highlighted Teva Pharmaceutical Industries Limited (NYSE:TEVA) arsenic 1 of its starring contributors. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is an Israel-based pharmaceutical company. On April 6, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) closed astatine $29.82 per share. One-month instrumentality of Teva Pharmaceutical Industries Limited (NYSE:TEVA) was -5.39%, and its shares gained 119.43% implicit the past 52 weeks. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has a marketplace capitalization of $35.58 billion.

ClearBridge Select Strategy stated the pursuing regarding Teva Pharmaceutical Industries Limited (NYSE:TEVA) successful its 4th fourth 2025 capitalist letter:

Portfolio banal enactment was somewhat affirmative (+373 bps) successful the quarter. The champion performing stocks successful the 4th were Dollar Tree (DLTR; 4.08%**), Teva Pharmaceutical Industries Limited (NYSE:TEVA) (TEVA; 2.17%**), and C.H. Robinson (CHRW; 3.41%**). Teva saw beardown maturation successful the 4th arsenic continued its strategical pivot toward branded pharmaceuticals, emphasizing CNS and immunology arsenic halfway therapeutic pillars. Additionally, deleveraging efforts are expected to little financing expenses by 2027, supporting semipermanent profitability.

Among Small-Cap Healthcare Stocks Hedge Funds is Buying

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 60 hedge money portfolios held Teva Pharmaceutical Industries Limited (NYSE:TEVA) astatine the extremity of the 4th quarter, the aforesaid arsenic successful the erstwhile quarter. While we admit the imaginable of Teva Pharmaceutical Industries Limited (NYSE:TEVA) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article